CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 179 enrolled
Drug / intervention
Comparator: MK0518 +3 moredrug
Likely dose
MK0518 200 mg, 400 mg, or 600 mg orally twice daily for 24 weeksAI-extracted
Key inclusion· 2
  • ✓HIV-positive with HIV RNA values within study-required ranges
  • ✓Currently on antiretroviral therapy (ART)
Key exclusion· 1
  • ✕Age less than 18 years

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00105157
NCT00105157Phase 2Completed
CompareCT.gov

Multicenter Study to Evaluate the Safety and Efficacy of MK0518 in Combination With An Optimized Background Therapy (OBT), Versus OBT Alone, in HIV-Infected Patients With Documented Resistance

Merck Sharp & Dohme LLC·interventional·Posted Mar 9, 2005·Updated Dec 4, 2015

In Brief

A Phase 2 clinical trial evaluating Comparator: MK0518, MK0518, and 1 other intervention for HIV Infections and Acquired Immunodeficiency Syndrome. Completed, enrolled 179 participants.

Detailed Summary

This study will investigate the safety and efficacy of different doses of an investigational drug (MK0518) as a therapy for HIV-infected patients failing current antiretroviral therapies.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections, Acquired Immunodeficiency Syndrome
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 9, 2005
Enrollment StartMar 1, 2005
Primary CompletionOct 1, 2006
Study CompletionJul 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 21.3 years ago

Interventions

Comparator: MK0518drug

MK0518 oral tablets 200 mg b.i.d, for 24 weeks

MK0518drug

MK0518 oral tablets 400 mg b.i.d, for 24 weeks

MK0518drug

MK0518 oral tablets 600 mg b.i.d, for 24 weeks

Placebodrug

Placebo to MK0518, oral tablet b.i.d, for 24 weeks